185 related articles for article (PubMed ID: 32396700)
1. Integrating oral PrEP delivery among African women in a large HIV endpoint-driven clinical trial.
Beesham I; Welch JD; Heffron R; Pleaner M; Kidoguchi L; Palanee-Phillips T; Ahmed K; Baron D; Bukusi EA; Louw C; Mastro TD; Smit J; Batting JR; Malahleha M; Bailey VC; Beksinska M; Donnell D; Baeten JM;
J Int AIDS Soc; 2020 May; 23(5):e25491. PubMed ID: 32396700
[TBL] [Abstract][Full Text] [Related]
2. Incorporating oral PrEP into standard prevention services for South African women: a nested interrupted time-series study.
Donnell D; Beesham I; Welch JD; Heffron R; Pleaner M; Kidoguchi L; Palanee-Phillips T; Ahmed K; Baron D; Bukusi EA; Louw C; Mastro TD; Smit J; Batting JR; Malahleha M; Bailey VC; Beksinska M; Rees H; Baeten JM;
Lancet HIV; 2021 Aug; 8(8):e495-e501. PubMed ID: 34126052
[TBL] [Abstract][Full Text] [Related]
3. Exploring the Use of Oral Pre-exposure Prophylaxis (PrEP) Among Women from Durban, South Africa as Part of the HIV Prevention Package in a Clinical Trial.
Beesham I; Heffron R; Evans S; Baeten JM; Smit J; Beksinska M; Mansoor LE
AIDS Behav; 2021 Apr; 25(4):1112-1119. PubMed ID: 33106996
[TBL] [Abstract][Full Text] [Related]
4. Integrating preexposure prophylaxis delivery in routine family planning clinics: A feasibility programmatic evaluation in Kenya.
Mugwanya KK; Pintye J; Kinuthia J; Abuna F; Lagat H; Begnel ER; Dettinger JC; John-Stewart G; Baeten JM;
PLoS Med; 2019 Sep; 16(9):e1002885. PubMed ID: 31479452
[TBL] [Abstract][Full Text] [Related]
5. Brief Report: Quantifiable Plasma Tenofovir Among South African Women Using Daily Oral Pre-exposure Prophylaxis During the ECHO Trial.
Beesham I; Mansoor LE; Joseph Davey DL; Palanee-Phillips T; Smit J; Ahmed K; Selepe P; Louw C; Singata-Madliki M; Kotze P; Heffron R; Parikh UM; Wiesner L; Rees H; Baeten JM; Beksinska M
J Acquir Immune Defic Syndr; 2022 Sep; 91(1):26-30. PubMed ID: 35972853
[TBL] [Abstract][Full Text] [Related]
6. Daily Oral Pre-exposure Prophylaxis (PrEP) Continuation Among Women from Durban, South Africa, Who Initiated PrEP as Standard of Care for HIV Prevention in a Clinical Trial.
Beesham I; Joseph Davey DL; Beksinska M; Bosman S; Smit J; Mansoor LE
AIDS Behav; 2022 Aug; 26(8):2623-2631. PubMed ID: 35122575
[TBL] [Abstract][Full Text] [Related]
7. Prospective study of oral pre-exposure prophylaxis initiation and adherence among young women in KwaZulu-Natal, South Africa.
Mansoor LE; Lewis L; Naicker CL; Harkoo I; Dawood H; Naidoo K; Gengiah TN; Samsunder N; Beesham I; Abdool Karim SS; Abdool Karim Q
J Int AIDS Soc; 2022 Jul; 25(7):e25957. PubMed ID: 35785472
[TBL] [Abstract][Full Text] [Related]
8. Enhancing HIV pre-exposure prophylaxis outcomes among Kenyan adolescent girls and young women with a novel pharmacy-based PrEP delivery platform: protocol for a cluster-randomized controlled trial.
Lagat HK; Pintye J; Harrington E; Houck S; Kwena Z; Lenn M; Mogaka F; Momanyi V; Mugambi M; Nyerere B; Odoyo J; Omollo V; Ortblad KF; Rota G; Sharma M; Bukusi EA
Trials; 2024 Jun; 25(1):394. PubMed ID: 38890744
[TBL] [Abstract][Full Text] [Related]
9. Post-trial access to and use of pre-exposure prophylaxis in Durban, South Africa.
Beesham I; Milford C; Smit J; Joseph Davey DL; Baeten JM; Heffron R; Beksinska M; Mansoor LE
BMC Public Health; 2023 Jun; 23(1):1210. PubMed ID: 37349816
[TBL] [Abstract][Full Text] [Related]
10. HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda.
Koss CA; Havlir DV; Ayieko J; Kwarisiima D; Kabami J; Chamie G; Atukunda M; Mwinike Y; Mwangwa F; Owaraganise A; Peng J; Olilo W; Snyman K; Awuonda B; Clark TD; Black D; Nugent J; Brown LB; Marquez C; Okochi H; Zhang K; Camlin CS; Jain V; Gandhi M; Cohen CR; Bukusi EA; Charlebois ED; Petersen ML; Kamya MR; Balzer LB
PLoS Med; 2021 Feb; 18(2):e1003492. PubMed ID: 33561143
[TBL] [Abstract][Full Text] [Related]
11. PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project.
Celum CL; Bukusi EA; Bekker LG; Delany-Moretlwe S; Kidoguchi L; Omollo V; Rousseau E; Travill D; Morton JF; Mogaka F; O'Malley G; Barnabee G; van der Straten A; Donnell D; Parikh UM; Kudrick L; Anderson PL; Haberer JE; Wu L; Heffron R; Johnson R; Morrison S; Baeten JM;
J Int AIDS Soc; 2022 Jul; 25(7):e25962. PubMed ID: 35822945
[TBL] [Abstract][Full Text] [Related]
12. Preferences for Long-Acting PrEP Products Among Women and Girls: A Quantitative Survey and Discrete Choice Experiment in Eswatini, Kenya, and South Africa.
Little KM; Hanif H; Anderson SM; Clark MR; Gustafson K; Doncel GF
AIDS Behav; 2024 Mar; 28(3):936-950. PubMed ID: 37971614
[TBL] [Abstract][Full Text] [Related]
13. Integrated provision of topical pre-exposure prophylaxis in routine family planning services in South Africa: a non-inferiority randomized controlled trial.
Mansoor LE; Yende-Zuma N; Baxter C; Mngadi KT; Dawood H; Gengiah TN; Samsunder N; Schwartz JL; Doncel GF; Abdool Karim Q
J Int AIDS Soc; 2019 Sep; 22(9):e25381. PubMed ID: 31507088
[TBL] [Abstract][Full Text] [Related]
14. My Way: development and preliminary evaluation of a novel delivery system for PrEP and other sexual health needs of young women in Western Kenya.
Haberer JE; Oware K; Juma L; Nyerere B; Momanyi V; Odoyo J; Garrison L; Bhagat J; Musinguzi N; Baeten JM; Siegler A; Bukusi EA
J Int AIDS Soc; 2024 Feb; 27(2):e26217. PubMed ID: 38379132
[TBL] [Abstract][Full Text] [Related]
15. Protocol for a longitudinal study to evaluate the use of tenofovir-based PrEP for safer conception and pregnancy among women in South Africa.
Matthews LT; Jaggernath M; Kriel Y; Smith PM; O'Neil K; Haberer JE; Hendrix C; Baeten JM; Ware NC; Wirth K; Psaros C; Bangsberg DR; Smit JA
BMJ Open; 2019 Jul; 9(7):e027227. PubMed ID: 31350241
[TBL] [Abstract][Full Text] [Related]
16. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium
Lancet; 2019 Jul; 394(10195):303-313. PubMed ID: 31204114
[TBL] [Abstract][Full Text] [Related]
17. Key stakeholders' perspectives on providing oral pre-exposure prophylaxis as HIV-prevention standard of care in clinical trials in South Africa.
Beesham I; Milford C; Joseph Davey DL; Smit J; Mansoor LE; Beksinska M
Afr J AIDS Res; 2023 Apr; 22(1):18-26. PubMed ID: 36951406
[No Abstract] [Full Text] [Related]
18. Alignment of adherence and risk for HIV acquisition in a demonstration project of pre-exposure prophylaxis among HIV serodiscordant couples in Kenya and Uganda: a prospective analysis of prevention-effective adherence.
Haberer JE; Kidoguchi L; Heffron R; Mugo N; Bukusi E; Katabira E; Asiimwe S; Thomas KK; Celum C; Baeten JM
J Int AIDS Soc; 2017 Jul; 20(1):21842. PubMed ID: 28741331
[TBL] [Abstract][Full Text] [Related]
19. HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery.
Celum CL; Delany-Moretlwe S; Baeten JM; van der Straten A; Hosek S; Bukusi EA; McConnell M; Barnabas RV; Bekker LG
J Int AIDS Soc; 2019 Jul; 22 Suppl 4(Suppl Suppl 4):e25298. PubMed ID: 31328444
[TBL] [Abstract][Full Text] [Related]
20. The Community PrEP Study: a randomized control trial leveraging community-based platforms to improve access and adherence to pre-exposure prophylaxis to prevent HIV among adolescent girls and young women in South Africa-study protocol.
Medina-Marino A; Bezuidenhout D; Hosek S; Barnabas RV; Atujuna M; Bezuidenhout C; Ngwepe P; Peters RPH; Little F; Celum CL; Daniels J; Bekker LG
Trials; 2021 Jul; 22(1):489. PubMed ID: 34311754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
